SI2327414T1 - Prekurzor N-acetilgalaktozamin-4-sulfataze, postopki zdravljenja z uporabo omenjenega encima in postopki izdelave in čiščenja omenjenega encima - Google Patents

Prekurzor N-acetilgalaktozamin-4-sulfataze, postopki zdravljenja z uporabo omenjenega encima in postopki izdelave in čiščenja omenjenega encima

Info

Publication number
SI2327414T1
SI2327414T1 SI200332419T SI200332419T SI2327414T1 SI 2327414 T1 SI2327414 T1 SI 2327414T1 SI 200332419 T SI200332419 T SI 200332419T SI 200332419 T SI200332419 T SI 200332419T SI 2327414 T1 SI2327414 T1 SI 2327414T1
Authority
SI
Slovenia
Prior art keywords
enzyme
methods
sulfatase
acetylgalactosamine
purifying
Prior art date
Application number
SI200332419T
Other languages
English (en)
Slovenian (sl)
Inventor
Minmin Qin
John M. Henstrand
Gary N. Zecherle
Dan J. Wendt
Wai-Pan Chan
Lin Chen
Paul A. Fitzpatrick
Christopher M. Starr
Stuart Swiedler
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of SI2327414T1 publication Critical patent/SI2327414T1/sl

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SI200332419T 2002-11-07 2003-11-07 Prekurzor N-acetilgalaktozamin-4-sulfataze, postopki zdravljenja z uporabo omenjenega encima in postopki izdelave in čiščenja omenjenega encima SI2327414T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/290,908 US6866844B2 (en) 2002-11-07 2002-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
EP10011421.4A EP2327414B1 (en) 2002-11-07 2003-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Publications (1)

Publication Number Publication Date
SI2327414T1 true SI2327414T1 (sl) 2015-05-29

Family

ID=32312121

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332419T SI2327414T1 (sl) 2002-11-07 2003-11-07 Prekurzor N-acetilgalaktozamin-4-sulfataze, postopki zdravljenja z uporabo omenjenega encima in postopki izdelave in čiščenja omenjenega encima

Country Status (17)

Country Link
US (1) US6866844B2 (enExample)
EP (2) EP2327414B1 (enExample)
JP (1) JP4459059B2 (enExample)
CN (1) CN100374157C (enExample)
AR (1) AR042019A1 (enExample)
AU (1) AU2003290642B2 (enExample)
BR (1) BRPI0316039B1 (enExample)
CA (1) CA2502928C (enExample)
CY (1) CY1116164T1 (enExample)
DK (1) DK2327414T3 (enExample)
ES (2) ES2533770T3 (enExample)
IL (1) IL168435A (enExample)
MX (1) MXPA05004880A (enExample)
PT (2) PT1565209E (enExample)
SI (1) SI2327414T1 (enExample)
TW (1) TWI327919B (enExample)
WO (1) WO2004043373A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ES2366059T3 (es) * 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
CN101539550B (zh) * 2009-04-28 2012-05-23 李绍平 用于多糖的定性与定量分析方法
MX382443B (es) 2010-06-25 2025-03-11 Shire Human Genetic Therapies Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
PE20130589A1 (es) * 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
CN103068999A (zh) * 2010-08-20 2013-04-24 贝林格尔.英格海姆国际有限公司 通过在获自细胞培养物的液体中改变ph灭活蛋白酶的方法
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN105848746B (zh) * 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (enExample) 1961-07-20
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
SE387536B (sv) 1973-03-13 1976-09-13 Astra Laekemedel Ab Forfarande for framstellning av en lokalanestetisk beredning
AU5577101A (en) 2000-05-01 2001-11-12 Biomarin Pharmaceuticals Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly

Also Published As

Publication number Publication date
EP2327414B1 (en) 2015-01-07
CY1116164T1 (el) 2017-02-08
BR0316039A (pt) 2005-09-13
ES2445028T3 (es) 2014-02-27
AR042019A1 (es) 2005-06-08
US20040101524A1 (en) 2004-05-27
ES2533770T3 (es) 2015-04-15
CN1726046A (zh) 2006-01-25
PT1565209E (pt) 2014-02-13
EP1565209A2 (en) 2005-08-24
PT2327414E (pt) 2015-04-13
CN100374157C (zh) 2008-03-12
HK1157215A1 (en) 2012-06-29
AU2003290642B2 (en) 2008-07-10
BRPI0316039B8 (enExample) 2021-05-25
CA2502928C (en) 2013-07-16
MXPA05004880A (es) 2005-07-22
BRPI0316039B1 (pt) 2017-08-29
CA2502928A1 (en) 2004-05-27
EP1565209A4 (en) 2008-01-02
DK2327414T3 (en) 2015-04-13
TWI327919B (en) 2010-08-01
US6866844B2 (en) 2005-03-15
WO2004043373A2 (en) 2004-05-27
WO2004043373A3 (en) 2004-08-05
TW200427459A (en) 2004-12-16
IL168435A (en) 2014-07-31
EP1565209B1 (en) 2013-11-06
JP4459059B2 (ja) 2010-04-28
AU2003290642A1 (en) 2004-06-03
EP2327414A1 (en) 2011-06-01
JP2006510356A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
SI1561756T1 (sl) Postopek čiščenja proteinov
AU2002339844A1 (en) Screening and therapeutic methods for promoting wakefulness and sleep
AU2003278361A1 (en) Method of water treatment
AU2002349630A1 (en) Medical treatment system and production method therefor
AU2003280298A1 (en) Methods for the biological treatment of gas
AU2002354439A1 (en) Nanocarbon-dissolving aqueous solution, aqueous solution for purification, and method of purification
SI2327414T1 (sl) Prekurzor N-acetilgalaktozamin-4-sulfataze, postopki zdravljenja z uporabo omenjenega encima in postopki izdelave in čiščenja omenjenega encima
ZA200309302B (en) Process for production of formed honeycomb body, and honeycomb structure.
AU2003235506A8 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2003260778A1 (en) Treatment of pipes
EP1544291A4 (en) A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF
AU2003221005A1 (en) Method of wastewater treatment
AU2003266998A1 (en) Microstructured catalyst body and method for production thereof
AU2002951011A0 (en) Water treatment process
AU2002951913A0 (en) Method of treatment
GB0217493D0 (en) Novel methods of treatment
GB0208897D0 (en) New method of treatment
EP1771709A4 (en) CURVED PANEL FOR SOUNDPROOFING COATING, METHOD FOR THE PRODUCTION THEREOF AND SOUNDPROOFING COVERING THEREWITH
GB0221712D0 (en) Methods of treatment
AU2003268651A1 (en) Method of purifying protein complex, assay method, purification device and assay device
GB0213198D0 (en) Method of treatment
GB0207091D0 (en) Method of treatment
AUPS219902A0 (en) Methods of treatment
AU2002953042A0 (en) Method of treatment
AUPS079602A0 (en) Method of treatment